Search

Your search keyword '"Ferry, Robert J Jr."' showing total 12 results
Start Over Author "Ferry, Robert J Jr." Search Limiters Peer Reviewed
12 results on '"Ferry, Robert J Jr."'

2. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

Author

Sherry, Nicole, Hagopian, William, Ludvigsson, Johnny, Jain, Sunil M, Wahlen, Jack, Ferry, Robert J, Jr, Bode, Bruce, Aronoff, Stephen, Holland, Christopher, Carlin, David, King, Karen L, Wilder, Ronald L, Pillemer, Stanley, Bonvini, Ezio, Johnson, Syd, Stein, Kathryn E, Koenig, Scott, Herold, Kevan C, and Daifotis, Anastasia G

Published
2011
Full Text
View/download PDF

12. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.

Author

Hagopian, William, Ferry Jr, Robert J, Sherry, Nicole, Carlin, David, Bonvini, Ezio, Johnson, Syd, Stein, Kathryn E, Koenig, Scott, Daifotis, Anastasia G, Herold, Kevan C, Ludvigsson, Johnny, Protégé Trial Investigators, and Ferry, Robert J Jr

Abstract

Protégé was a phase 3, randomized, double-blind, parallel, placebo-controlled 2-year study of three intravenous teplizumab dosing regimens, administered daily for 14 days at baseline and again after 26 weeks, in new-onset type 1 diabetes. We sought to determine efficacy and safety of teplizumab immunotherapy at 2 years and to identify characteristics associated with therapeutic response. Of 516 randomized patients, 513 were treated, and 462 completed 2 years of follow-up. Teplizumab (14-day full-dose) reduced the loss of C-peptide mean area under the curve (AUC), a prespecified secondary end point, at 2 years versus placebo. In analyses of prespecified and post hoc subsets at entry, U.S. residents, patients with C-peptide mean AUC >0.2 nmol/L, those randomized ≤6 weeks after diagnosis, HbA1c <7.5% (58 mmol/mol), insulin use <0.4 units/kg/day, and 8-17 years of age each had greater teplizumab-associated C-peptide preservation than their counterparts. Exogenous insulin needs tended to be reduced versus placebo. Antidrug antibodies developed in some patients, without apparent change in drug efficacy. No new safety or tolerability issues were observed during year 2. In summary, anti-CD3 therapy reduced C-peptide loss 2 years after diagnosis using a tolerable dose. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results